A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, single-center, randomized, double-blind, single ascending dose,
placebo-controlled study, in subjects aged 45-80 years with stable mild to moderate heart
failure due to left ventricular systolic dysfunction, to evaluate the safety, tolerability,
and pharmacokinetics of escalating single intravenous infusion doses of Bendavia™ (MTP-131).